NASDAQ:PVLA Palvella Therapeutics (PVLA) Stock Price, News & Analysis $124.15 -33.09 (-21.04%) Closing price 04:00 PM EasternExtended Trading$129.12 +4.97 (+4.00%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Palvella Therapeutics Stock (NASDAQ:PVLA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Palvella Therapeutics alerts:Sign Up Key Stats Today's Range$123.97▼$157.5550-Day Range$102.19▼$157.2452-Week Range$29.59▼$161.38Volume558,108 shsAverage Volume294,132 shsMarket Capitalization$1.78 billionP/E RatioN/ADividend YieldN/APrice Target$199.53Consensus RatingModerate Buy Company Overview Palvella Therapeutics, Inc. (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs. Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes. Utilizing its integrated chemistry and biology capabilities, the company seeks to optimize drug candidates for favorable pharmacokinetics, safety, and efficacy profiles. Palvella has also established strategic partnerships with academic institutions and industry collaborators to accelerate its research and development efforts. Headquartered in the United States, Palvella Therapeutics operates a dedicated research and development center where its multidisciplinary team of experts in immunology, medicinal chemistry, and clinical sciences drives program advancement. Since its inception, the company has demonstrated a commitment to expanding its pipeline through both internal discovery and external collaborations, with the ultimate goal of bringing new treatment options to patients suffering from debilitating inflammatory diseases.AI Generated. May Contain Errors. Read More Palvella Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScorePVLA MarketRank™: Palvella Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 372nd out of 840 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingPalvella Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 1 strong buy rating, 14 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPalvella Therapeutics has a consensus price target of $199.53, representing about 60.7% upside from its current price of $124.15.Amount of Analyst CoveragePalvella Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Palvella Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Palvella Therapeutics are expected to decrease in the coming year, from ($5.26) to ($6.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palvella Therapeutics is -29.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palvella Therapeutics is -29.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalvella Therapeutics has a P/B Ratio of 52.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Palvella Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.93% of the float of Palvella Therapeutics has been sold short.Short Interest Ratio / Days to CoverPalvella Therapeutics has a short interest ratio ("days to cover") of 6.31.Change versus previous monthShort interest in Palvella Therapeutics has recently increased by 13.93%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPalvella Therapeutics does not currently pay a dividend.Dividend GrowthPalvella Therapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.96 News SentimentPalvella Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Palvella Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for PVLA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added Palvella Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Palvella Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $476,360.00 in company stock.Percentage Held by Insiders17.20% of the stock of Palvella Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.11% of the stock of Palvella Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Palvella Therapeutics' insider trading history. Receive PVLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palvella Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PVLA Stock News HeadlinesPalvella Therapeutics (NASDAQ:PVLA) Shares Up 5.7% - Still a Buy?July 19 at 4:21 AM | americanbankingnews.comPalvella Therapeutics Corporate Event Calendar | NASDAQ:PVLAJuly 18 at 6:04 PM | benzinga.comMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.July 20 at 1:00 AM | Paradigm Press (Ad)Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 18 at 3:15 AM | americanbankingnews.comPalvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORINJuly 15, 2026 | insidermonkey.comPalvella Therapeutics Adds Industry Veteran to BoardJune 30, 2026 | tipranks.comPalvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of DirectorsJune 30, 2026 | globenewswire.comKathleen Goin Sells 4,302 Shares of Palvella Therapeutics (NASDAQ:PVLA) StockJune 23, 2026 | insidertrades.comSee More Headlines PVLA Stock Analysis - Frequently Asked Questions How have PVLA shares performed this year? Palvella Therapeutics' stock was trading at $104.67 at the beginning of 2026. Since then, PVLA stock has increased by 18.6% and is now trading at $124.15. How were Palvella Therapeutics' earnings last quarter? Palvella Therapeutics, Inc. (NASDAQ:PVLA) posted its earnings results on Thursday, May, 7th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.90) by $0.30. Read the conference call transcript. How do I buy shares of Palvella Therapeutics? Shares of PVLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/07/2026Today7/20/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (18m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 PVLA's financial health is in the Green zone, according to TradeSmith. PVLA has been in this zone for over 18 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PVLA Previous SymbolNASDAQ:PVLA CIK1583648 Webwww.pieris.com Phone857-246-8998Fax49-8161-141-1444EmployeesN/AYear Founded2015Price Target and Rating Average Price Target for Palvella Therapeutics$199.53 High Price Target$270.00 Low Price Target$90.00 Potential Upside/Downside+60.7%Consensus RatingModerate Buy Rating Score (0-4)2.94 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($4.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$41.72 million Net MarginsN/A Pretax MarginN/A Return on Equity-56.87% Return on Assets-42.50% Debt Debt-to-Equity RatioN/A Current Ratio28.88 Quick Ratio28.88 Sales & Book Value Annual Sales$42.81 million Price / Sales41.59 Cash FlowN/A Price / Cash FlowN/A Book Value$2.36 per share Price / Book52.61Miscellaneous Outstanding Shares14,340,000Free Float11,876,000Market Cap$1.78 billion OptionableN/A Beta-0.20 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:PVLA) was last updated on 7/20/2026 by MarketBeat.com Staff. From Our PartnersBacked Company Could Save Power GridA small Colorado company holds the rights to technology that could protect the U.S. public power grid from col...Altimetry | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | SponsoredNVIDIA offered $40B. The answer was no.Apple, NVIDIA, Google, Amazon, and Samsung all pay one company billions in royalties every year. NVIDIA tried ...Behind the Markets | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredTrump is positioned. Elon lights the fuse.Earlier this year, the Trump-backed World Liberty Trust applied for a federal banking charter. Now, new report...Crypto 101 Media | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
